Graphique du cours de l'action IKT
IKT Gagner
Inhibikase Therapeutics Inc
$1.89
0.53%
$0.01
À la fermeture : Apr 27, 16:00:00 GMT-4
$1.86
-1.58%
$-0.02
Pré-Marché: Apr 28, 08:58:05 GMT-4
Retour
Inhibikase Therapeutics Inc (IKT) Gagner
Statistiques clés
Clôture préc.
$1.88
Prix d'ouverture
$1.86
Plage de la journée
$1.85 - $1.92
Plage de 52 semaines
$1.33 - $2.36
Volume
688.9K
Volume moyen
1.5M
Rendement en dividend
--
BPA (TTM)
-1.15
Capitalisation boursière
$245.5M
Qu’est-ce que IKT ?
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.